📰 Genentech News
Page 98 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
September 21, 2023
The Roche-owned U.S. giant Genentech has teamed up with the Japanese biotech Peptidream to co-develop peptide-based radiopharmaceutical treatments.
September 21, 2023
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and...
September 21, 2023
After announcing a $1 billion radiopharma deal with PeptiDream, Genentech signed a separate deal with Orionis Biosciences for its molecular glue degraders to target cancer and neurodegeneration.
September 20, 2023
(RTTNews) - Japan-based biopharmaceutical company PeptiDream Inc. said that it has collaborated with U.S.-based Genentech, a member of the Roche...
September 20, 2023
The Japanese biopharma will receive $40 million upfront from Genetech for R&D of its macrocyclic peptide-radioisotope drug conjugates, with another $1 billion on the line in milestone payments.
September 20, 2023
The collaboration will focus on discovering novel small molecule therapies for cancer and neurodegenerative diseases, using Orionis’ Allo-Glue platform.
September 20, 2023
Peptidream Inc. and Genentech Inc., a Roche Holding company, signed a deal worth up to $1 billion to discover and develop macrocyclic peptide-radioisotope (peptide-RI) drug conjugates. Peptidream, of Kawasaki, Japan, will use its peptide discovery platform system technology to discover, optimize and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech. Genentech will pay Peptidream an up-front payment of $40 million and up to $1 bi...
September 20, 2023
Over the past day, Genentech has been making a concerted bid to expand its partnered portfolio into the hottest R&D areas. | Only hours after the Roche unit…